Back to top
more

Fate Therapeutics (FATE)

(Delayed Data from NSDQ)

$3.91 USD

3.91
1,587,276

+0.01 (0.26%)

Updated May 20, 2024 04:00 PM ET

After-Market: $3.91 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for FATE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Fate Therapeutics, Inc. [FATE]

Reports for Purchase

Showing records 361 - 380 ( 426 total )

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 361

05/09/2016

Company Report

Pages: 6

1Q, Expecting Valuation Disconnect to Correct with ProTmune Data this Year, Reiterate OP

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 362

03/04/2016

Company Report

Pages: 6

4Q15 Update: ProTmune Preparing to Enter Clinic; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 363

03/03/2016

Company Report

Pages: 6

4Q15: Focus is on ProTmune Development as FATE Completes Year of Transition, Reiterate OP but Reducing PT to $8 (from $10) on Dilution Concerns

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 364

02/24/2016

Daily Note

Pages: 3

The Best of Both Worlds in Hematopoietic Transplant: Delivering Graft-vs-Leukemia Activity with Low Graft-vs-Host Risk

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 365

12/11/2015

Industry Report

Pages: 12

Spotlight on Cell and Gene Therapy at ASH 2015

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 366

12/09/2015

Company Report

Pages: 8

Punting on ProHema, ProTmune Takes Center Stage; Revising PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 367

12/07/2015

Daily Note

Pages: 5

ASH Update Supports ProTmune Development, In Human Study to Start in 2016, Reiterate Outperform

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 368

12/07/2015

Daily Note

Pages: 5

ASH Update Supports ProTmune Development, In Human Study to Start in 2016, Reiterate Outperform

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 369

12/04/2015

Industry Report

Pages: 5

Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 7th

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 370

11/20/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 371

11/09/2015

Industry Report

Pages: 7

ASH 2015 Abstract Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 372

11/09/2015

Industry Report

Pages: 7

Biotechnology/Biopharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 373

11/04/2015

Company Report

Pages: 9

3Q15 Update: Evolving Pipeline Places Emphasis on Fully-Customizable Cellular Immunotherapies

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 374

11/04/2015

Company Report

Pages: 8

FATE 3Q, Changing our Valuation, Reducing Focus on ProHema in Favor of More Promising ProTmune Program, Maintain OP but Trimming our PT to $10

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 375

10/30/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 2This report contains brief updates on the following: DYAX, ANAC, IRWD, ECYT, FATE, XNCR, RGLS, MGNX, FCSC, SNSS, INFI, MDVN, RPTP, SRPT, XOMA, AGTC, EPZM, BLUE, PTCT, CATB, EPRS, ABUS, ICPT. These companies are covered in more detail in separate Daily Notes and/or Company Reports.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 376

10/13/2015

Industry Report

Pages: 7

Highlights from the Meeting on the Mesa: Looking Beyond Stem Cells in Regenerative Medicine

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 377

08/12/2015

Industry Report

Pages: 30

HEALTHCARE: 2015 HCMAC Day 1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 378

08/12/2015

Daily Note

Pages: 30

2015 HCMAC Day 1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 379

08/06/2015

Company Report

Pages: 10

2Q15 Update-Forays into Cellular Immunotherapy and Multiple Clinical Readouts Could Drive Shareholder Value

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 380

08/05/2015

Company Report

Pages: 5

Q2:EPS; Pivotal Trial Data Ahead; Building Broad Pipeline with Expanding Network of Collaborators

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party